PHASE II TRIAL OF PACLITAXEL IN PATIENTS WITH ADVANCED COLON CANCER PREVIOUSLY UNTREATED WITH CYTOTOXIC CHEMOTHERAPY
| Autor: | Peter H. Wiernik, Peter J. O'Dwyer, Nicholas J. Petrelli, Donna Neuberg, Guillermo Ramirez, Avi I. Einzig, Louise B. Grochow |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Pharmacology
Oncology medicine.medical_specialty Group trial Colorectal cancer business.industry Rectum General Medicine Cytotoxic chemotherapy medicine.disease digestive system diseases chemistry.chemical_compound medicine.anatomical_structure Paclitaxel chemistry Internal medicine Toxicity medicine Adenocarcinoma Pharmacology (medical) In patient business |
| Zdroj: | American Journal of Therapeutics. 3:750-754 |
| ISSN: | 1075-2765 |
| DOI: | 10.1097/00045391-199611000-00003 |
| Popis: | Paclitaxel was administered as a 24-h continuous infusion at 250 mg/m(2) in this Phase II trial in patients with adenocarcinoma of the colon or rectum. Nineteen patients were evaluated for toxity and 15 were assessable for response. There were no complete or partial responses, and toxicity present was primarily neutropenia. This study found that paclitaxel as a single agent does not have activity in adenocarcinoma of the colon or rectum. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|